NCT05155033View on ClinicalTrials.gov

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

August 18, 2022

Primary Completion Date

September 1, 2031

Study Completion Date

September 1, 2031

Conditions
Metastatic MelanomaAdvanced Locoregional MelanomaMetastatic Renal Cell CarcinomaClear Cell Histology
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg IV over approximately 30 minutes on Day 1 of cycles 1 and 2 during Courses 1 and 2.

DRUG

Aldesleukin

Aldesleukin (IL-2) administration \[600,000 IU/kg IV bolus every 8 hours continuing for up to 4 days (maximum 10 doses)\] starting on Day 1 of cycles 1 and 2 during Course 1.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH